[go: up one dir, main page]

DE69828614D1 - Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6 - Google Patents

Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6

Info

Publication number
DE69828614D1
DE69828614D1 DE69828614T DE69828614T DE69828614D1 DE 69828614 D1 DE69828614 D1 DE 69828614D1 DE 69828614 T DE69828614 T DE 69828614T DE 69828614 T DE69828614 T DE 69828614T DE 69828614 D1 DE69828614 D1 DE 69828614D1
Authority
DE
Germany
Prior art keywords
antibodies
beta
treatment
renal fibrosis
integrin alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69828614T
Other languages
English (en)
Other versions
DE69828614T2 (de
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Application granted granted Critical
Publication of DE69828614D1 publication Critical patent/DE69828614D1/de
Publication of DE69828614T2 publication Critical patent/DE69828614T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69828614T 1997-08-08 1998-08-07 Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6 Expired - Lifetime DE69828614T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
US55060P 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (2)

Publication Number Publication Date
DE69828614D1 true DE69828614D1 (de) 2005-02-17
DE69828614T2 DE69828614T2 (de) 2006-02-09

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69840113T Expired - Lifetime DE69840113D1 (de) 1997-08-08 1998-08-07 Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern
DE69828614T Expired - Lifetime DE69828614T2 (de) 1997-08-08 1998-08-07 Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69840113T Expired - Lifetime DE69840113D1 (de) 1997-08-08 1998-08-07 Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern

Country Status (23)

Country Link
US (5) US20020004482A1 (de)
EP (3) EP1504764B1 (de)
JP (2) JP2001513333A (de)
KR (1) KR100586202B1 (de)
CN (1) CN1267224A (de)
AT (3) ATE410179T1 (de)
AU (1) AU739283B2 (de)
BR (1) BR9814040A (de)
CA (1) CA2297736A1 (de)
CY (2) CY1110462T1 (de)
CZ (1) CZ299768B6 (de)
DE (2) DE69840113D1 (de)
DK (2) DK1930022T3 (de)
EE (1) EE04752B1 (de)
ES (3) ES2364703T3 (de)
HU (1) HU228900B1 (de)
IL (2) IL134288A0 (de)
NZ (2) NZ515955A (de)
PL (2) PL201716B1 (de)
PT (3) PT1504764E (de)
RU (1) RU2221589C2 (de)
TR (2) TR200202323T2 (de)
WO (1) WO1999007405A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
EP1504764B1 (de) * 1997-08-08 2008-10-08 The Regents Of The University Of California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern
GEP20063844B (en) * 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
CA2478833C (en) 2002-03-13 2015-11-10 Biogen, Inc. Anti-.alpha.v.beta.6 antibodies
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP1734996B1 (de) * 2004-04-02 2013-05-22 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
EP2046374A4 (de) 2006-07-10 2010-05-05 Biogen Idec Inc Zusammensetzungen und verfahren zur wachstumshemmung von smad4-defizienten tumoren
CN103524619B (zh) * 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
EP2087008A1 (de) * 2006-10-19 2009-08-12 The Regents of the University of California BEHANDLUNG UND PRÄVENTION VON CHRONISCHEM ASTHMA MIT INTEGRIN-alphaVbeta6-ANTAGONISTEN
EP2537529B1 (de) * 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2-hemmer antikörper und verwendungen davon
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
KR20120054077A (ko) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
JP2013502226A (ja) 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． リシル酸化酵素及びｌｏｘｌ２由来の触媒ドメイン
CA2789022A1 (en) * 2010-02-04 2011-08-11 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP2814509B1 (de) 2012-02-17 2018-05-16 Seattle Genetics, Inc. Antikörper gegen integrin v6 und verwendung davon zur behandlung von krebs
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP2784511A1 (de) 2013-03-27 2014-10-01 Universität Zürich Integrin-alpha-v-beta 6 zur Diagnose/Prognose von Kolorektalkarzinomen
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
HK1254295A1 (zh) * 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体
KR20200044066A (ko) 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
CA3159414A1 (en) 2019-12-05 2021-06-10 Seagen Inc. Anti-av.beta.6 antibodies and antibody-drug conjugates
EP4520329A3 (de) * 2020-05-07 2025-05-14 Pliant Therapeutics, Inc. Behandlung von atemwegserkrankungen mit aminosäureverbindungen
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
FI912858A7 (fi) 1988-12-20 1991-06-13 La Jolla Cancer Res Foundation Haavojen parantamisessa aktiivisia polypeptidipolymeerikonjugaatteja
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
EP1504764B1 (de) * 1997-08-08 2008-10-08 The Regents Of The University Of California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern

Also Published As

Publication number Publication date
DE69840113D1 (de) 2008-11-20
IL134288A0 (en) 2001-04-30
US6316601B1 (en) 2001-11-13
ES2364703T3 (es) 2011-09-12
AU8774398A (en) 1999-03-01
RU2221589C2 (ru) 2004-01-20
US20010056076A1 (en) 2001-12-27
ATE511850T1 (de) 2011-06-15
ES2311131T3 (es) 2009-02-01
HUP0003547A2 (hu) 2001-02-28
PT1930022E (pt) 2011-08-01
US7544358B2 (en) 2009-06-09
KR20010022740A (ko) 2001-03-26
TR200202323T2 (tr) 2002-12-23
BR9814040A (pt) 2000-10-03
JP2001513333A (ja) 2001-09-04
CZ299768B6 (cs) 2008-11-19
PL341029A1 (en) 2001-03-26
HU228900B1 (en) 2013-06-28
US20040208878A1 (en) 2004-10-21
EP1504764B1 (de) 2008-10-08
PT1504764E (pt) 2009-01-14
US6692741B2 (en) 2004-02-17
KR100586202B1 (ko) 2006-06-07
EP1504764A1 (de) 2005-02-09
JP2009001587A (ja) 2009-01-08
EP1930022B1 (de) 2011-06-08
EE04752B1 (et) 2006-12-15
NZ502546A (en) 2002-02-01
EP0996460A4 (de) 2001-03-07
EP0996460B1 (de) 2005-01-12
EE200000068A (et) 2000-10-16
PT996460E (pt) 2005-04-29
DE69828614T2 (de) 2006-02-09
PL199014B1 (pl) 2008-08-29
NZ515955A (en) 2003-04-29
HUP0003547A3 (en) 2002-05-28
EP0996460A1 (de) 2000-05-03
US7150871B2 (en) 2006-12-19
ATE410179T1 (de) 2008-10-15
ATE286742T1 (de) 2005-01-15
WO1999007405A1 (en) 1999-02-18
CA2297736A1 (en) 1999-02-18
US20070148173A1 (en) 2007-06-28
CY1111792T1 (el) 2015-10-07
US20020004482A1 (en) 2002-01-10
IL134288A (en) 2008-07-08
ES2235350T3 (es) 2005-07-01
EP1930022A1 (de) 2008-06-11
AU739283B2 (en) 2001-10-11
TR200000374T2 (tr) 2000-09-21
CY1110462T1 (el) 2015-04-29
CN1267224A (zh) 2000-09-20
CZ2000413A3 (cs) 2000-11-15
PL201716B1 (pl) 2009-05-29
DK1930022T3 (da) 2011-07-25
DK1504764T3 (da) 2008-11-17

Similar Documents

Publication Publication Date Title
DE69828614D1 (de) Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
FI963101A7 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
DE122007000002I1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DK1007089T3 (da) Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose
PT1411064E (pt) ''anticorpos recombinantes associados a gangliósidos e sua utilização no diagnóstico e tratamento de tumores''
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE60237447D1 (de) Verwendung von polyklonalen anti-hiv ziegenseren als therapeutisches mittel
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE69613168D1 (de) Verwendung eines CGRP Antagonisten zur Behandlung von Flechten und Pruritus und so erhaltene Zubereitung
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
FR2822087B1 (fr) Materiau composite ameliore pour le traitement d'effluents photographiques
RU99123884A (ru) Способ лечения параноидной шизофрении
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine
UA38888A (uk) Спосіб лікування хронічного вірусного гепатиту
DE69000237D1 (de) Bleichfixier-regenerationssatz und verwendung davon in photographischer behandlung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition